This assumption is consistent with Boissière-Michot et al. [16] who recently pointed out that especially in rectal cancer after CRT false negative detection of the KRAS mutation status represents a relevant problem possibly leading to serious malpractice. The gene discussed is KRAS; the disease is rectal cancer.